Experimental drug BL-M02D1 takes first steps against tough cancers

NCT ID NCT05385692

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an experimental drug called BL-M02D1 in 22 people with advanced gastrointestinal or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M02D1 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced gastrointestinal or other solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 22 participants, focused mainly on safety and dosing. The drug may not prove effective, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC DIGESTIVE TRACT TUMORS SOLID TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.